Parvinen I, Paukkala E
J Clin Pharmacol. 1979 Aug-Sep;19(8-9 Pt 2):533-9. doi: 10.1002/j.1552-4604.1979.tb02519.x.
Thirty patients with mild to severe essential hypertension satisfactorily controlled by twice-daily sotalol therapy entered a double-blind, crossover study comparing the efficacy, tolerability, and safety of their usual twice-daily sotalol administration with the same dosage given once daily. Each double-blind period extended eight weeks, during which blood pressure and pulse rate were recorded by a nurse three times daily on alternate days during the last week of each period in the patients' usual living conditions. Plasma sotalol concentration was measured before the morning dosage of sotalol. No statistically significant differences in the parameters were found between once- and twice-daily sotalol administration using sotalol in daily dosages from 80 to 320 mg. All patients concluded the trial, and no increase in side effects was noted during the once-daily period.
30例轻度至重度原发性高血压患者,通过每日两次服用索他洛尔治疗,血压得到满意控制,他们进入了一项双盲交叉研究,比较每日两次服用常规剂量索他洛尔与每日一次服用相同剂量索他洛尔的疗效、耐受性和安全性。每个双盲期持续8周,在此期间,在每个阶段的最后一周,护士在患者正常生活条件下每隔一天每天三次记录血压和脉搏率。在早晨服用索他洛尔之前测量血浆索他洛尔浓度。使用每日剂量80至320mg的索他洛尔,每日一次和每日两次给药之间在参数上未发现统计学上的显著差异。所有患者均完成试验,在每日一次给药期间未发现副作用增加。